Time from medication order to administration of cabazitaxel (C) vs. lutetium Lu-177 vipivotide tetraxetan (Lu) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Y Yeonjung Jo (Huntsman Cancer Institute at The University of Utah, Salt Lake City, UT) C Chadi Hage Chehade (Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA) Z Zeynep Irem Ozay (Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA) G Georges Gebrael (Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA) N Nicolas Sayegh (Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA) R Richard Hardy S Siqi Hu N Nishita Tripathi (Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT) B Beverly Chigarira (3IntegraConnect PrecisionQ, West Palm Beach, United States) B Blake Nordblad (Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT) R Richard Ji (Huntsman Cancer Institute, University of Utah, Salt Lake City, UT) D Diya Garg (Huntsman Cancer Institute, University of Utah, Salt Lake City, UT) G Gliceida M Galarza Fortuna (Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT) V Vinay Mathew Thomas (Huntsman Cancer Institute at The University of Utah, Salt Lake City, UT) H Haoran Li (Zhejiang University , , 866 Yuhangtang Rd , ,) S Soumyajit Roy B Benjamin L. Maughan (University of Utah, Salt Lake City, UT) I Irbaz Bin Riaz (Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA) N Neeraj Agarwal (Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA) U Umang Swami (Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA)

Abstract

109 Background: C and Lu are associated with overall survival benefit and approved for pts with mCRPC after prior treatment with docetaxel and an androgen receptor pathway inhibitor (ARPI). However, in real-world settings, administering Lu requires coordination across specialties and resources [PMID: 36637862], which could delay its administration. Herein, we sought to compare the time from medication order to administering the first dose of C versus Lu. Methods: This study used pt level data from the nationwide Flatiron Health electronic health record (EHR)-derived de-identified database. Inclusion criteria: availability of the date of the first order of single-agent C or Lu and the date of first administration of the drugs. The time between the first medication order to the administration of single-agent C or Lu was measured. Wilcoxon rank-sum test was used to compare the median days between medication order to administration between these 2 agents and a stratified analysis by practice type and insurance was performed. Results: Of 2,329 orders, 2,045 orders were for C between 1/1/2013 and 1/26/2024, while 284 were for Lu between 8/1/2013 and 12/6/2023. The time from medication order to administration was significantly longer with Lu (median 22 days, IQR 12-43) compared to C (median 7 days, IQR 3-14, p < 0.001). Time from medication order to administration of C and Lu by practice type and insurance is summarized (Table). At the time of the first order, pts in Lu cohort, compared to C cohort, were significantly older (median age 74 vs. 72, p < 0.001), more likely to be treated at an academic practice (27% vs. 15%, p < 0.001), and more likely to be covered by a commercial health plan (80% vs. 73%, p < 0.001). Conclusions: Our results show that it takes significantly longer to administer Lu compared to C across different practice types and most insurance plans. These results could inform healthcare policies aimed at improving access to Lu and guide treatment selection in the clinic. Time from medication order to administration of C and Lu by practice type and insurance. Category Subtype (number of orders for C/number of orders for Lu) CN = 2045 LuN = 284 p-value Practice type, mean (range) (days) Academic (315/77) 1.3 (0 – 59) 9.2 (0 – 55) < 0.001 Community (1730/207) 13 (0 – 243) 44 (1 – 282) < 0.001 Insurance, mean (range) (days) Commercial (1494/226) 11 (0 – 163) 32 (0 – 215) < 0.001 Medicare/other government programs (266/46) 10 (0 – 120) 46 (0 – 282) < 0.001 Medicaid (32/2) 9 (0 – 76) 28 (0 – 55) 0.8 Others (72/6) 12 (0 – 42) 21 (0 – 41) 0.2 Unknown (181/4) 14 (0 – 243) 76 (39 – 91) < 0.001

Article Details

Volume / Issue Vol. 43, Issue 5_suppl
Published February 10, 2025
Pages 109-109
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (20)

Y

Yeonjung Jo

Huntsman Cancer Institute at The University of Utah, Salt Lake City, UT

C

Chadi Hage Chehade

Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA

Z

Zeynep Irem Ozay

Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA

G

Georges Gebrael

Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA

N

Nicolas Sayegh

Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA

R

Richard Hardy

S

Siqi Hu

N

Nishita Tripathi

Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

B

Beverly Chigarira

3IntegraConnect PrecisionQ, West Palm Beach, United States

B

Blake Nordblad

Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

R

Richard Ji

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

D

Diya Garg

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

G

Gliceida M Galarza Fortuna

Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

V

Vinay Mathew Thomas

Huntsman Cancer Institute at The University of Utah, Salt Lake City, UT

H

Haoran Li

Zhejiang University , , 866 Yuhangtang Rd , ,

S

Soumyajit Roy

B

Benjamin L. Maughan

University of Utah, Salt Lake City, UT

I

Irbaz Bin Riaz

Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA

N

Neeraj Agarwal

Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA

U

Umang Swami

Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA